

AMENDMENTS TO THE CLAIMS

Listing of claims:

1. (Currently Amended) An injectable formulation comprising a ~~A~~ pharmaceutical composition consisting essentially of FSH and hCG in at least one pharmaceutically acceptable carrier, wherein the amount of FSH and hCG is selected from the group consisting of: 50 IU FSH and 100 IU hCG; 50 IU FSH and 200 IU hCG; 75 IU FSH and 25 IU hCG; 75 IU FSH and 50 IU hCG; 75 IU FSH and 75 IU hCG; 75 IU FSH and 100 IU hCG; 150 IU FSH and 25 IU hCG; 150 IU FSH and 50 IU hCG; 150 IU FSH and 75 IU hCG; and 150 IU FSH and 100 IU hCG.
- 2-6. (Cancelled)
7. (Currently Amended) The injectable formulation ~~pharmaceutical composition~~ of claim 1 wherein the amount of FSH and hCG is selected from the group consisting of (i) 50 IU FSH and 100 IU hCG, and (ii) 50 IU FSH and 200 IU hCG, ~~and 50 IU FSH and 400 IU hCG.~~
8. (Currently Amended) The injectable formulation ~~pharmaceutical composition~~ of claim 7, wherein the amount of FSH and hCG is 50 IU FSH and 100 IU hCG.
- 9-10. (Cancelled)
11. (Currently Amended) The injectable formulation ~~pharmaceutical composition~~ according to claim 1, wherein said FSH is human derived FSH.
12. (Currently Amended) The injectable formulation ~~pharmaceutical composition~~ according to claim 1, in lyophilised form.
13. (Currently Amended) The injectable formulation ~~pharmaceutical composition~~ according to claim 1, in unit dosage form.
14. (Cancelled)
15. (Cancelled)

16. (Currently Amended) The injectable formulation ~~pharmaceutical composition~~ according to claim 1 in liquid form.
17. (Currently Amended) The injectable formulation ~~pharmaceutical composition~~ according to claim 16 wherein the liquid form is supplied in a vial.
18. (Currently Amended) The injectable formulation ~~pharmaceutical composition~~ according to claim 16 wherein the liquid form is supplied in a pre-filled syringe or cartridge.
19. (Currently Amended) An assemblage comprising a first vial and a second vial, each of said vials containing an injectable formulation ~~pharmaceutical composition~~ according to ~~any of~~ claim 1, wherein the ~~ratio~~ amounts of FSH and hCG ~~differ~~ differs between the first vial and the second vial.
- 20-33. (Cancelled)
34. (Currently Amended) A product comprising a first pharmaceutical composition comprising recombinant FSH and a second pharmaceutical composition comprising recombinant hCG wherein the amount of recombinant hCG in the second pharmaceutical composition is selected from the group consisting of 1, 2, 3, 4 or 8 μ g hCG.
- 35-36. (Cancelled)
37. (Currently Amended) The product of claim 34, further comprising a ~~means~~ syringe for administering the first and second pharmaceutical compositions.
- 38-44. (Cancelled).
45. (Currently Amended) A product comprising a first pharmaceutical composition comprising recombinant FSH and a second pharmaceutical composition comprising recombinant hCG wherein the amount of recombinant FSH in the first pharmaceutical composition is from about ~~1-0~~ 0.1 μ g to about 2,000 mg/ml.

46. (Currently Amended) A product comprising a first pharmaceutical composition comprising recombinant FSH and a second pharmaceutical composition comprising recombinant hCG wherein the amount of recombinant hCG in the second pharmaceutical composition is about 0.1 μ g to about 2,000 mg/ml.
47. (Currently Amended) A product comprising a first pharmaceutical composition comprising recombinant FSH and a second pharmaceutical composition comprising recombinant hCG wherein the amount of recombinant FSH in the first pharmaceutical composition is from about ~~1-9~~ 0.1 μ g to about 2,000 mg/ml and the amount of recombinant hCG in the second pharmaceutical composition is about 0.1 μ g to about 2,000 mg/ml.

48-49. (Cancelled)